GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Affimed
Affimed is a biotech company developing immunotherapy for cancer treatment. Its stock price is volatile and depends on the results of clinical trials and partnerships with major pharmaceutical companies that validate its technology platform.
Share prices of companies in the market segment - Pharma immune
Affimed is a German biopharmaceutical company developing innovative cancer immunotherapy that activates NK cells and T cells. We've categorized it under "Pharma: Immunology." The chart below shows how investors evaluate new approaches in immuno-oncology.
Broad Market Index - GURU.Markets
Affimed is a German biopharmaceutical company developing immunotherapeutic drugs that activate natural killer cells (NK cells) to fight cancer. As a component of the GURU.Markets index, it represents the immuno-oncology sector. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
AFMD - Daily change in the company's share price Affimed
Affimed N.V.'s daily share price fluctuations reflect the extreme volatility inherent in immuno-oncology companies. This metric measures the sensitivity to news about clinical trials of its NK cell-engaging platform.
Daily change in the price of a set of shares in a market segment - Pharma immune
Affimed develops innovative NK cell-based immunotherapy for cancer treatment. The immuno-oncology sector is highly volatile and rapidly growing. The chart below reflects the average fluctuations in this field, helping to assess the risks and dynamics of AFMD stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Affimed is a German biotech company focused on immunology. Its US-listed shares bring the dynamics of the European biotech sector to the market. These international factors make the overall picture of market volatility more complex and global.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Affimed
Affimed N.V.'s year-over-year performance tells the story of its unique platform for developing immuno-oncology drugs. Its market capitalization growth over the past 12 months reflects progress in clinical trials of its molecules, which "attract" NK cells to fight cancer. Partnerships with major companies are a testament to its technology.
Annual dynamics of market capitalization of the market segment - Pharma immune
Affimed N.V. is a clinical-stage biotech company developing a new class of cancer immunotherapy. Its stock performance is entirely dependent on the results of clinical trials and partnerships. The chart reflects the enormous potential of its scientific platform and the high risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Affimed, a pioneer in cancer immunotherapy using innate immune cells, is developing next-generation technology. Its year-over-year market capitalization reflects investor confidence in its scientific platform. Clinical data and partnerships with major pharma are the main drivers of its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Affimed
Affimed is a German immuno-oncology company. Its monthly performance is driven by progress in clinical trials of its Redirected Optimized Cell Killing (ROCK®) platform. Positive data and news of partnerships with major pharmaceutical companies are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Affimed develops innovative immunotherapeutics that target innate immune cells (NK cells) to fight cancer. The chart below reflects the overall sentiment in the immunological pharmaceutical sector, where Affimed offers a unique approach.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Affimed N.V. is a biotech company developing immunotherapy for cancer treatment. Its shares are driven by clinical trial results and partnership news. The company's performance is virtually uncorrelated with the broader market, betting on scientific success.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Affimed
Shares of Affimed, a German company developing cancer immunotherapy, are extremely volatile. Weekly price movements depend entirely on news about clinical trials and partnerships with major pharmaceutical companies. The chart below illustrates how short-term scientific developments and investor expectations can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Affimed is developing a platform for creating immuno-oncology drugs. The potential of these technologies is enormous, but the risks are also high. The chart will show how investors evaluate the company's scientific prospects, causing its shares to move at their own pace, distinct from the overall healthcare sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Affimed develops cancer immunotherapy. This chart shows how its weekly performance, like that of other biotechs, is detached from the market. Share movements are driven by news about clinical trials and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
AFMD - Market capitalization of the company Affimed
Affimed N.V.'s valuation on the chart is a bet on its unique platform for creating molecules (Innate Cell Engagers) that direct innate immune cells to fight cancer. The company's market capitalization depends on the success of its clinical trials. The dynamics illustrate the potential of this new approach in immuno-oncology.
AFMD - Share of the company's market capitalization Affimed within the market segment - Pharma immune
Affimed's stake in immuno-oncology is based on its unique ICE technology, which enables the creation of antibodies that direct immune cells to destroy tumors. Its market share reflects the potential of this platform to develop a new class of cancer drugs.
Market capitalization of the market segment - Pharma immune
Here's a chart of the total market capitalization of biotech companies developing NK cell-based immunotherapy. Affimed is a leader in this field. The graph shows how the market values this promising but highly competitive cancer technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market value of an innovative approach in immuno-oncology. Affimed's market capitalization is the valuation of its platform for creating molecules that "train" immune cells to attack cancer cells. The line shows how this cutting-edge German biotechnology company is shaping its stake in the future of cancer treatment.
Book value capitalization of the company, segment and market as a whole
AFMD - Book value capitalization of the company Affimed
The graph below shows the scientific foundation of Affimed N.V. Its line represents the value of the intellectual property for the platform for creating NK cell enhancers for cancer immunotherapy. An increase in the graph indicates progress in clinical trials, which are the company's main asset.
AFMD - Share of the company's book capitalization Affimed within the market segment - Pharma immune
Affimed's core assets are its laboratories and R&D centers for developing unique immuno-oncology drugs that target NK cells. The chart shows the company's share of this cutting-edge scientific infrastructure, which forms the physical foundation of its innovative platform.
Market segment balance sheet capitalization - Pharma immune
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Affimed, as an immunotherapy developer, has a more streamlined model. Its value lies in its unique scientific platform, not in the scale of its production.
Book value of all companies included in the broad market index - GURU.Markets
Affimed is developing a unique class of immunotherapy (Innate Cell Engagers) for cancer treatment. The company's assets include a cutting-edge scientific platform and manufacturing capabilities for creating these "bridges" for immune cells. The chart below illustrates the financial weight behind this innovative technology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Affimed
Affimed is a German immuno-oncology company. Its market value is derived from its unique platform for creating antibodies that activate the immune system against cancer. Investors are buying a stake in its cutting-edge science.
Market to book capitalization ratio in a market segment - Pharma immune
Affimed N.V. is a biotech company developing a platform for activating immune cells to fight cancer. Its value is based on the potential of this technology. This chart shows how its market valuation, reflecting hopes for a breakthrough in immunotherapy, is many times greater than its current assets.
Market to book capitalization ratio for the market as a whole
Affimed is a biopharmaceutical company developing immunotherapy for cancer treatment. The market valuation shown in this chart is based on the potential of their unique technology platform. The dynamics reflect investor expectations for clinical trials.
Debts of the company, segment and market as a whole
AFMD - Company debts Affimed
Affimed, an immuno-oncology company, is using raised capital to develop its Innate Cell Enhancer (ICE®) platform. This chart shows how the company is funding its numerous clinical trials, often in partnership with major pharma companies, to prove the effectiveness of its cancer treatment approach.
Market segment debts - Pharma immune
Affimed is developing an innovative platform for the creation of immunotherapeutic drugs (NK cell energizers) for the treatment of cancer. This chart shows how its debt policy reflects the capital requirements to finance an extensive clinical trial program for its cutting-edge technology and its path to potential commercialization.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Affimed
Agrify produces equipment and software for vertical farming, including cannabis cultivation. This is a fast-growing but capital-intensive market. This chart shows how the company uses debt to finance its production and expansion.
Market segment debt to market segment book capitalization - Pharma immune
Affimed is a clinical-stage biotech developing immunotherapeutic drugs based on its ICE (Innate Cell Engager) platform. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company is funding its innovative approaches to cancer treatment.
Debt to book value of all companies in the market
Affimed N.V. develops innovative immuno-oncology drugs that direct immune system cells to fight cancer. This cutting-edge biotechnology requires significant investment. This chart of total market debt helps understand the financial environment in which Affimed is raising capital for its expensive clinical trials.
P/E of the company, segment and market as a whole
P/E - Affimed
This chart shows the valuation of Affimed, an immuno-oncology company. It lacks consistent revenue, so its P/E ratio is not a key metric. Its value is determined by progress in clinical trials and partnerships with major pharmaceutical companies that believe in its scientific platform.
P/E of the market segment - Pharma immune
Affimed develops innovative immuno-oncology drugs that activate innate immune cells (NK cells and macrophages) to fight cancer. Their platform enables the creation of multi-target antibodies. This chart shows the average valuation for the pharmaceutical sector, reflecting investor expectations for the next generation of immunotherapeutic approaches.
P/E of the market as a whole
Affimed is developing an innovative class of NK cell-based immunotherapeutics for cancer treatment. The company's technology aims to create a bridge between immune cells and tumor cells. This risk appetite chart helps understand how investors evaluate new immuno-oncology platforms.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Affimed
Affimed is developing innovative NK cell-based immunotherapy for cancer treatment. Its ICE platform enables the creation of antibodies that target immune cells to tumors. This chart demonstrates investor confidence in the potential of this technology. Future profits depend on the success of clinical trials.
%20P%2FE%20Affimed&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Affimed&v=1772552392485 "Chart of the company's future (projected) P/E Affimed")
Future (projected) P/E of the market segment - Pharma immune
Affimed is developing a platform for creating NK cell immunotherapeutics for cancer treatment. This chart reflects how investors view its unique technology. It compares expectations for Affimed with other companies in the fast-growing field of immuno-oncology, demonstrating confidence in its scientific approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772552392502 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Affimed is developing innovative immunotherapy based on innate immune cells (NK cells) for the treatment of cancer. The company's future depends on clinical success. This chart, reflecting market optimism, shows investor willingness to invest in cutting-edge but high-risk biotech platforms, which is what drives Affimed's funding.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772552392535 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Affimed
Affimed is a clinical-stage immuno-oncology company developing a platform for creating antibodies that direct immune cells to destroy tumors. Its financial performance is driven by partnerships and R&D expenditures. This chart shows how advance payments from major pharmaceutical companies fund its expensive research.
Profit of companies in the market segment - Pharma immune
Affimed develops innovative NK cell-based immunotherapeutics for cancer treatment. This graph, showing overall sector revenue, reflects the potential of new approaches in immuno-oncology. Success of Affimed's platform could lead to more effective and safer treatments and have a significant impact on the entire industry.
Overall market profit
Affimed develops innovative NK cell immunotherapeutics for cancer treatment. The company's platform enables the creation of powerful and precise tools to combat tumors. Its future depends on clinical data demonstrating the effectiveness and safety of this approach.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Affimed
Affimed develops innovative immuno-oncology drugs to activate immune cells against cancer. Future revenue estimates are speculative and depend on clinical trial results. Analysts are evaluating the potential of its Redirected Optimized Cell Killing (ROCK®) platform.
%20profit%20of%20the%20company%20Affimed&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Affimed&v=1772552392672 "Graph of future (projected) profit of the company Affimed")
Future (predicted) profit of companies in the market segment - Pharma immune
Affimed develops innovative immuno-oncology drugs that target natural killer (NK) cells and T cells to fight tumors. This chart shows revenue projections for the entire immunotherapy segment. It allows one to assess how the company's unique technology platform compares to overall expectations for this cutting-edge field of oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772552392841 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Affimed develops innovative NK cell immunotherapeutics for cancer treatment. As with many biotech companies, this chart is important for Affimed as an indicator of investor risk appetite. Positive economic outlooks facilitate the raising of significant capital required for costly clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772552392944 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Affimed
Affimed N.V. is a clinical-stage biotechnology company developing innovative immunotherapy for cancer treatment. This metric, which correlates market capitalization with revenue from collaborations, is a measure of the valuation of its technology platform. It reflects the premium investors are paying for its unique approach to activating immune cells.
P/S market segment - Pharma immune
Affimed N.V. develops innovative immunotherapeutics based on its platform for redirecting innate immune cells (NK cells and macrophages) to fight cancer. This chart shows the market premium for revenue in the immuno-oncology sector, demonstrating investor confidence in Affimed's unique technology platform.
P/S of the market as a whole
Affimed N.V. is a clinical-stage biopharmaceutical company developing innovative immuno-oncology therapies for NK and T-cell activation. This chart, reflecting the average valuation, demonstrates that investors value the company based on the potential of its unique technology platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Affimed
Affimed N.V. develops innovative immunotherapeutic drugs for the treatment of cancer. This chart shows the market's assessment of its potential future revenue from drugs in development. It reflects investor confidence in its unique technology and the success of clinical trials conducted jointly with partners.
%20P%2FS%20Affimed&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Affimed&v=1772552393129 "The graph of the company's future (projected) P/S Affimed")
Future (projected) P/S of the market segment - Pharma immune
Affimed is developing an innovative platform of NK cell and T cell activators for the treatment of oncology. The chart shows the average estimated future revenue in the immunology sector. It helps understand how the market views Affimed's unique technology and its potential to create a new class of immuno-oncology drugs compared to other approaches.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772552393171 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Affimed (AFMD) develops innovative immuno-oncology drugs that activate a patient's own immune cells to fight cancer. Their future depends on the success of clinical trials. This schedule has nothing to do with their scientific developments, which could change approaches to cancer treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772552393231 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Affimed
This chart shows the revenue of Affimed, a biotech developing immunotherapeutic drugs to fight cancer. Being in the clinical stage, its revenue comes not from sales but from upfront and milestone payments through major partnerships with companies like Roche and Genentech.
Sales of companies in the market segment - Pharma immune
Affimed N.V. is developing innovative immunotherapy for cancer treatment based on its ICE (Innate Cell Engager) platform. Currently in the clinical stage, its revenue comes from partnerships with major pharmaceutical companies. Future revenue depends on the success of its own and partner programs.
Overall market sales
Affimed N.V. is a biopharmaceutical company developing immunotherapeutic drugs for cancer treatment. Its success depends on the results of clinical trials and partnerships with major pharmaceutical companies. The overall economic situation, reflected in this chart, influences the funding available to the biotech sector and the strategic budgets of potential partners.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Affimed
Affimed N.V. develops innovative immunotherapeutic drugs for the treatment of cancer that activate innate immune cells. Future revenue depends on the success of its clinical trials. This chart reflects analysts' long-term expectations for its platform.
%20sales%20of%20the%20company%20Affimed&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Affimed&v=1772552393351 "Schedule of future (projected) sales of the company Affimed")
Future (projected) sales of companies in the market segment - Pharma immune
Affimed N.V. is developing innovative NK cell-based immunotherapy for the treatment of cancer. This chart shows the outlook for the immunology pharmaceutical segment. It reflects the high demand for new approaches in immuno-oncology, creating a favorable environment for clinical development and partnerships for the Affimed platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772552393390 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
This chart reflects investment appetite in biotech, which is critical for Affimed. The company develops immuno-oncology drugs. Its ability to partner with major pharmaceutical companies and attract funding is directly dependent on a positive economic outlook.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772552393416 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Affimed
Affimed develops innovative immuno-oncology drugs that harness innate immune cells (NK cells) to fight tumors. This chart reflects its investment in cutting-edge science. Future profitability depends on the success of clinical trials and potential partnerships with major pharmaceutical companies.
Market segment marginality - Pharma immune
Affimed is a biopharmaceutical company developing innovative immuno-oncology drugs based on its platform that activates innate immune cells. Profitability depends on the success of its unique approach. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential and risks associated with Affimed's technology.
Market marginality as a whole
Affimed develops innovative immunotherapeutic drugs for cancer treatment. As a clinical-stage biotech company, it relies on investment to fund its research. This chart shows the overall market willingness to invest in risky but promising scientific platforms. This directly impacts Affimed's ability to continue its operations.
Employees in the company, segment and market as a whole
Number of employees in the company Affimed
Affimed N.V. develops innovative immuno-oncology drugs that direct immune cells to destroy cancer cells. This chart shows the size of the research and clinical teams. The growth in the chart reflects progress in clinical trials and expanding partnerships with major pharmaceutical companies, confirming the potential of their technological platform.
Share of the company's employees Affimed within the market segment - Pharma immune
Affimed develops innovative immunotherapeutics that target innate immune cells (NK cells and macrophages) to fight cancer. This chart shows the company's share of all scientists in this cutting-edge field. This reflects its unique technology platform and scientific leadership.
Number of employees in the market segment - Pharma immune
Affimed N.V. is a biopharmaceutical company developing immunotherapeutics based on its platform for redirecting NK and T cells to tumors. This chart, showing employment in the immunopharmaceutical sector, is important. The growing number of scientists in this field reflects the intensive search for new ways to harness innate and adaptive immunity to fight cancer.
Number of employees in the market as a whole
Affimed develops unique immunotherapeutic drugs to combat cancer. Their success depends on continued R&D funding. This overall employment chart reflects the investment climate. During periods of economic growth, venture capital and large pharmaceutical companies increasingly invest in promising biotech platforms like Affimed's.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Affimed (AFMD)
Affimed (AFMD) is a German immuno-oncology company developing a platform for activating NK and T cells to fight cancer. This chart reflects the company's high intellectual capital valuation. The market values the potential of their scientific platform (Rock) rather than the current performance of their small R&D staff.
%20of%20the%20company%20Affimed%20(AFMD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Affimed-AFMD&v=1772552394035 "Chart of market capitalization per employee (in thousands of dollars) of the company Affimed (AFMD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Affimed develops unique immunotherapeutic drugs for cancer treatment. The company's value lies in its proprietary technology platform and clinical developments. This metric demonstrates how highly the market values intellectual capital in biotech, where a small team of scientists can create technology worth billions.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772552394063 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Affimed develops immunotherapeutic drugs for cancer treatment that activate NK cells and macrophages. The company's market capitalization reflects the potential of its unique technological platform. This metric demonstrates the company's enormous cost per employee, typical for biotech, where a small scientific team possesses breakthrough technology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772552394159 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Affimed (AFMD)
Affimed is a biotech company developing the "ICE" (Innate Cell Engagers) platform for activating innate immunity (NK cells) to fight cancer. This is cutting-edge R&D. This chart shows the company's capital burn rate: how much the company invests (negative return) per scientist to advance this complex immunotherapy.
%20Chart%20Affimed%20(AFMD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Affimed-AFMD&v=1772552394252 "Company Profit Per Employee (in thousands of dollars) Chart Affimed (AFMD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Affimed N.V. is a clinical immuno-oncology company developing innovative drugs. At the clinical trial stage, this metric reflects the effectiveness of R&D management. Investors monitor this performance in the context of research results, as successful trials can lead to multi-billion dollar partnerships with major pharmaceutical companies.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772552394335 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Affimed (AFMD) is a German biopharmaceutical company developing immuno-oncology drugs (based on NK cell activation). It is a clinical-stage R&D company with no profit. This metric is negative and reflects the "cost" of a single scientist working in the cutting-edge field of immunotherapy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772552394484 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Affimed (AFMD)
Affimed N.V. develops innovative drugs for cancer immunotherapy. During clinical development, the majority of revenue comes from partnerships with major pharmaceutical companies. This chart reflects the success of their scientific platform in attracting investment and partnerships.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Affimed-AFMD&v=1772552394547 "Sales chart per company employee Affimed (AFMD)")
Sales per employee in the market segment - Pharma immune
Affimed is a clinical-stage biotech developing an NK cell "enthusiast" (ICE) platform for cancer immunotherapy. This chart reflects their R&D status. Revenue (if any) comes from partnerships. The productivity of their scientific team lies in advancing this innovative platform through clinical trials.
Sales per employee for the market as a whole
Grupo Aval (AVAL) is one of the largest banking conglomerates in Colombia (and Central America), managing several leading banks (such as Banco de Bogotá). It is a systemic financial institution. This chart for a major bank shows the efficiency of its vast network. It reflects the income (interest and commission) generated by each employee, from branch tellers to investment bankers.
Short shares by company, segment and market as a whole
Shares shorted by company Affimed (AFMD)
Affimed (AFMD) is a German biotech company focused on immuno-oncology. This chart shows the volume of short positions. Short positions reflect the high risk of clinical trial failure, which is typical in this complex sector.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Affimed-AFMD&v=1772552394661 "Short Shares Chart for the Company Affimed (AFMD)")
Shares shorted by market segment - Pharma immune
Affimed (AFMD) is a German biotech developing an immunotherapy platform (NK cells) for cancer treatment. The chart below shows the aggregate short position in the immuno-oncology sector. It shows how many investors are skeptical of new cell therapy platforms, fearing failure.
Shares shorted by the overall market
Affimed (AFMD) is a clinical-stage biotech. Its value reflects the hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Affimed (AFMD)
This oscillator for Affimed is an indicator of faith in their immune cell retargeting (ICE®) platform. The company is developing drugs that "train" NK cells to attack cancer. "Overbought" (above 70) occurs due to positive trial data, especially in combination with other drugs. High competition in immuno-oncology leads to "oversold" levels.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Affimed-AFMD&v=1772552394839 "RSI 14 indicator chart for the company's stock Affimed (AFMD)")
RSI 14 Market Segment - Pharma immune
Affimed is a biotech company (Germany), an immune system "engineer." Their platform (ROCK) creates "recruiters" (bi-specifics) that direct NK cells (natural killer cells) to attack cancer. The "Pharma-immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is AFMD's growth due to their R&D, or is the entire biotech industry "overheated"?
RSI 14 for the overall market
Affimed (AFMD) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AFMD (Affimed)
Affimed (AFMD) is a German immuno-oncology company developing affinity molecules (ICE) that link NK cells (immune cells) to cancer cells. This chart shows the average price target. It reflects analysts' confidence in this technology and the data from its clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AFMD-Affimed&v=1772552394954 "A chart showing analyst consensus forecasts for the expected stock price. AFMD (Affimed)")
The difference between the consensus estimate and the actual stock price AFMD (Affimed)
Affimed (AFMD) is a German biotech company pioneering the redirection of immune cells (NK cells) to attack cancer (ICE platform). This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in this innovative R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AFMD-Affimed&v=1772552395037 "A chart showing the difference between the consensus forecast and the actual stock price. AFMD (Affimed)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Affimed is a biotech company developing an innovative immunotherapy (the ICE platform) that targets NK cells (innate immunity) against cancer. This chart shows analysts' overall expectations for the immune pharma sector. It reflects whether experts believe NK cell therapy will achieve breakthroughs.
Analysts' consensus forecast for the overall market share price
Affimed (AFMD) is a German biopharmaceutical company. They develop "NK cell enhancers"—smart antibodies that train the innate immune system (NK cells) to fight cancer. This chart shows the overall risk appetite. It reflects the willingness of investors to fund breakthrough but high-risk R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Affimed
Affimed is a German biotech R&D company focused on immuno-oncology. Their signature R&D platform (ICE®) creates bridges (bispecific antibodies) that connect innate immune cells (NK cells) with cancer cells. This graph is a clear indicator of their faith in R&D. It reflects their progress in clinical trials and their (critical) partnerships with big pharma.
AKIMA Market Segment Index - Pharma immune
Affimed is a German biopharmaceutical company developing cancer immunotherapy. Their technology harnesses innate immune cells (NK cells) to fight tumors. This chart compares their composite index to the sector, showing how their approach to innate immunity compares to others.
The AKIM Index for the overall market
Affimed is an immuno-oncology company developing innate immune inducers (ICEs) to activate NK cells against cancer. This chart, which reflects the market average, provides a macro backdrop. It helps assess how AFMD, a clinical-stage scientific story, compares to overall economic trends.
